• 1. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 2. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 3. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 4. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 5. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565

Professional Introduction to 2-Ethynyl-4-(trifluoromethyl)aniline (CAS No. 878133-02-9)

2-Ethynyl-4-(trifluoromethyl)aniline, with the chemical identifier CAS No. 878133-02-9, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical and materials science research. This compound, characterized by its ethynyl and trifluoromethyl substituents on an aniline backbone, exhibits unique chemical properties that make it a valuable intermediate in the synthesis of various high-performance materials and bioactive molecules.

The presence of the ethynyl group (?C≡H) in the molecular structure imparts reactivity that is conducive to further functionalization through processes such as Sonogashira coupling, which is widely used in constructing carbon-carbon bonds in organic synthesis. This reactivity is particularly useful in the development of complex molecular architectures, including those relevant to medicinal chemistry. On the other hand, the trifluoromethyl (?CF?) group introduces electron-withdrawing effects and steric hindrance, which can modulate the electronic properties and metabolic stability of derived compounds. These features are highly sought after in drug design, where optimizing both potency and selectivity is crucial.

In recent years, 2-Ethynyl-4-(trifluoromethyl)aniline has been explored as a key intermediate in the synthesis of novel pharmaceutical agents. Its structural motifs have been incorporated into molecules targeting various therapeutic areas, including oncology, inflammation, and central nervous system disorders. For instance, researchers have leveraged its reactivity to develop small-molecule inhibitors that interact with specific biological targets by exploiting the compound's ability to form stable covalent bonds with biomolecules. The trifluoromethyl group's influence on metabolic pathways has also been studied extensively, as it can enhance binding affinity and prolong half-life in drug candidates.

The compound's potential extends beyond pharmaceutical applications into the realm of advanced materials. The combination of electron-rich and electron-deficient regions in its structure makes it a candidate for use in organic electronics, such as light-emitting diodes (OLEDs) and photovoltaic cells. The ethynyl group can serve as a site for polymerization or cross-linking, while the trifluoromethyl substituent can improve thermal stability and chemical resistance. Such properties are increasingly important as industries move toward more sustainable and efficient technologies.

Recent advancements in synthetic methodologies have further enhanced the utility of 2-Ethynyl-4-(trifluoromethyl)aniline. Techniques such as transition-metal-catalyzed reactions have enabled more efficient and selective transformations, allowing chemists to access previously inaccessible derivatives with greater ease. These developments have not only accelerated research but also opened new avenues for innovation across multiple disciplines. For example, palladium-catalyzed cross-coupling reactions have been employed to introduce diverse functional groups at specific positions within the molecule, tailoring its properties for specific applications.

The study of 2-Ethynyl-4-(trifluoromethyl)aniline also contributes to our understanding of structure-activity relationships (SAR) in drug discovery. By systematically modifying its core structure and evaluating the impact on biological activity, researchers can gain insights into how different substituents influence molecular behavior. This knowledge is critical for designing next-generation drugs with improved efficacy and reduced side effects. Additionally, computational modeling techniques have been employed to predict the interactions between this compound and biological targets, providing a rational basis for experimental design.

In conclusion, 2-Ethynyl-4-(trifluoromethyl)aniline (CAS No. 878133-02-9) represents a versatile building block with broad applications in both pharmaceuticals and materials science. Its unique structural features enable a wide range of synthetic possibilities, making it an indispensable tool for chemists working on cutting-edge research. As our understanding of its properties continues to grow, so too will its role in developing innovative solutions to complex challenges across multiple industries.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)